Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2024
0mins
Should l Buy ?
Source: Business Insider
Analyst Ratings: Shane Storey from Wilsons has maintained a Buy rating on Telix Pharmaceuticals Ltd. with a price target of A$22.00, while the stock currently trades at $14.51. The analyst consensus for the company is a Strong Buy with a price target of $16.49, indicating a potential upside.
Company Overview: Telix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing targeted radiation therapies for prostate, renal, and glioblastoma cancers, operating in regions including Australia, the U.S., Belgium, and Japan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
